国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (7): 978-982.DOI: 10.3760/cma.j.issn.1007-1245.2023.07.020

• 临床研究 • 上一篇    下一篇

奥美拉唑注射液联合肠内营养支持治疗急性胰腺炎患者的效果

张琪  赵燕超   

  1. 徐州医科大学附属医院消化内科,徐州 221002

  • 收稿日期:2022-11-21 出版日期:2023-04-01 发布日期:2023-04-28
  • 通讯作者: 赵燕超,Email:yama790130@yahoo.co.jp
  • 基金资助:

    徐州市科技项目(KC21185

Effect of omeprazole injection combined with enteral nutrition support on patients with acute pancreatitis

Zhang Qi, Zhao Yanchao   

  1. Department of Gastroenterology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China

  • Received:2022-11-21 Online:2023-04-01 Published:2023-04-28
  • Contact: Zhao Yanchao, Email: yama790130@yahoo.co.jp
  • Supported by:

    Xuzhou Science and Technology Project (KC21185)

摘要:

目的 探讨奥美拉唑注射液联合肠内营养支持治疗对急性胰腺炎患者症状改善及预后的影响。方法 本文为随机对照试验。选取20201月至20221月徐州医科大学附属医院收治的96例急性胰腺炎患者,采用随机数字表法分为A组、B组和C组,各32例。A组男16例、女16例,年龄(46.89±7.58)岁;B组男17例、女15例,年龄(45.85±6.99)岁;C组男18例、女14例,年龄(45.02±7.74)岁。C组采用常规综合疗法,B组在C组基础上采用肠内营养支持治疗,A组在B组基础上给予奥美拉唑注射液。对比3组患者治疗效果,临床症状改善时间,治疗前后血清淀粉酶(AMS)、白细胞计数(WBC),预后。采用单因素方差分析、SNK-q检验、配对t检验、χ2检验、秩和检验。结果 A组总有效率[93.75%30/32)]高于B组[75.00%24/32)]、C组[62.50%20/32)],差异有统计学意义(χ2=4.857P=0.032)。A组腹痛缓解时间、排气恢复时间、AMS恢复时间及住院时间[(4.63±0.63d、(5.91±1.01d、(5.08±0.78d、(9.87±1.22d]均短于B组[(6.58±0.91d、(6.89±1.23d、(8.21±1.49d、(11.59±1.89d]、C组[(8.56±1.54d、(8.54±1.55d、(9.28±1.65d、(13.55±2.32d],差异均有统计学意义(F=67.97122.66254.33220.555,均P<0.001)。治疗后,AAMSWBC水平[(68.75±21.28U/L、(8.86±1.27×109/L]均低于B组[(118.83±38.92U/L、(10.02±2.13×109/L]、C组[(125.74±39.74U/L、(13.74±2.38×109/L],差异均有统计学意义(F=8.7412.965,均P<0.05)。A组预后不良发生率[12.50%4/32)]与B组[15.63%5/32)]、C组[18.75%6/32)]比较,差异无统计学意义(χ2=0.258P=0.784)。结论 在急性胰腺炎治疗中,奥美拉唑注射液联合肠内营养支持治疗能够促进患者相关指标较快恢复,改善临床症状,缩短住院时长,值得进一步研究及推广。

关键词:

急性胰腺炎, 奥美拉唑注射液, 肠内营养支持, 预后

Abstract:

Objective To investigate the effect of omeprazole injection combined with enteral nutrition support on the symptom improvement and prognosis in patients with acute pancreatitis. Methods It was a randomized controlled trial. A total of 96 patients with acute pancreatitis admitted in Affiliated Hospital of Xuzhou Medical University from January 2020 to January 2022 were divided into group A, group B, and group C by the random number table method with 32 patients in each group. There were 16 males and 16 females in group A, with an age of (46.89±7.58) years old; there were 17 males and 15 females in group B, with an age of (45.85±6.99) years old; there were 18 males and 14 females in group C, with an age of (45.02±7.74) years old. Group C received conventional comprehensive therapy, group B received enteral nutrition support therapy on the basis of group C, and group A received omeprazole injection on the basis of group B. The therapeutic effect, clinical symptom improvement time, serum amylase (AMS) and white blood cell count (WBC) before and after treatment, and prognosis were compared among the three groups. One-way analysis of variance, SNK-q test, paired t test, χ2 test, and rank sum test were used. Results The total effective rate of group A [93.75% (30/32)] was higher than those of group B [75.00% (24/32)] and group C [62.50% (20/32)], with a statistically significant difference (χ2=4.857, P=0.032). The abdominal pain relief time, exhaust recovery time, AMS recovery time, and length of hospital stay in group A [(4.63±0.63) d, (5.91±1.01) d, (5.08±0.78) d, and (9.87±1.22) d] were shorter than those in group B [(6.58±0.91) d, (6.89±1.23) d, (8.21±1.49) d, and (11.59±1.89) d] and group C [(8.56±1.54) d, (8.54±1.55) d, (9.28±1.65) d, and (13.55±2.32) d], with statistically significant differences (F=67.971, 22.662, 54.332, and 20.555; all P<0.001). After treatment, the levels of AMS and WBC in group A [(68.75±21.28) U/L and (8.86±1.27) ×109/L] were lower than those in group B [(118.83±38.92) U/L and (10.02±2.13) ×109/L] and group C [(125.74±39.74) U/L and (13.74±2.38) ×109/L], with statistically significant differences (F=8.741 and 2.965; both P<0.05). There was no statistically significant difference in the incidence of poor prognosis among group A [12.50% (4/32)], group B [15.63% (5/32)], and group C [18.75% (6/32)] (χ2=0.258, P=0.784). Conclusion In the treatment of acute pancreatitis, omeprazole injection combined with enteral nutrition support can promote the recovery of relevant clinical indicators, improve the clinical symptoms, and reduce the length of hospital stay, which is worthy of further study and promotion.

Key words:

Acute pancreatitis, Omeprazole injection, Enteral nutrition support, Prognosis